My name's Holly and I work in the Policy and Campaigns team at Breast Cancer Now.
The National Institute for Health and Care Excellence (NICE) is currently assessing talazoparib (also known as Talzenna) to see if it can be made available on the NHS for treating HER2 negative locally advanced or secondary (metastatic) breast cancer with germline BRCA1/2 mutations.
As part of this assessment, it's crucial that NICE hears the voice of patients. That's why I'm looking to hear from people with experience of this treatment. If you'd be happy to share your views on this treatment with me, please do email email@example.com.
Your views will be shared completely anonymously.